Cross-protection of commercial vaccines against Chilean swine influenza A virus using the guinea pig model as a surrogate

被引:0
|
作者
Tapia, Rodrigo [1 ]
Mena, Juan [1 ]
Garcia, Victoria [1 ]
Culhane, Marie [2 ]
Medina, Rafael A. [3 ,4 ,5 ]
Neira, Victor [1 ]
机构
[1] Univ Chile, Fac Ciencias Vet, Med Prevent Anim, Santiago, Chile
[2] Univ Minnesota, Coll Vet Med, Vet Populat Med, St Paul, MN USA
[3] Emory Univ, Sch Med, Dept Pathol & Expt Med, Atlanta, GA USA
[4] Icahn Sch Med Mt Sinai, Dept Microbiol, New York, NY USA
[5] Pontificia Univ Catolica Chile, Escuela Med, Dept Enfermedades Infecciosas Inmunol Pediat, Santiago, Chile
关键词
influenza; swine; vaccine; cross-protection; guinea pig model; surrogate; NEURAMINIDASE; TRANSMISSION;
D O I
10.3389/fvets.2023.1245278
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
Influenza A virus poses a significant threat to public health and the swine industry. Vaccination is the primary measure for controlling the disease, but the effectiveness of vaccines can vary depending on the antigenic match between vaccine strains and circulating strains. In Chile, H1N1pdm09 and other lineages H1N2 and H3N2 have been detected in pigs, which are genetically distinct from the strains included in commercial vaccines. This study aimed to evaluate the cross-protection by commercial vaccines against strains circulating in Chile using the guinea pig model. For this study, four circulating strains [A/swine/Chile/H1A-7/2014(H1N2), A/swine/Chile/H1B-2/2014(H1N2), A/swine/Chile/H1P-12/2015(H1N1), and A/swine/Chile/H3-2/2015(H3N2)] were selected. Guinea pigs were divided into vaccinated and control groups. The vaccinated animals received either a multivalent antigenically heterologous or monovalent homologous vaccine, while the control animals remained unvaccinated. Following vaccination, all animals were intranasally challenged, and nasal wash samples were collected at different time points post-infection. The results showed that the homologous monovalent vaccine-induced hemagglutinin-specific antibodies against the Chilean pandemic H1N1pdm09 strain. However, the commercial heterologous multivalent vaccine failed to induce hemagglutinin-specific antibody titers against the H1N2 and H3N2 challenge strains. Furthermore, the homologous monovalent vaccine significantly reduced the duration of viral shedding and viral titers specifically against the Chilean pandemic H1N1pdm09 strain and heterologous multivalent vaccine only partial. These findings highlight the importance of regularly updating vaccine strains to match the circulating field strains for effective control of swine influenza. Further research is needed to develop vaccines that confer broader protection against diverse strains of swine influenza A virus.
引用
收藏
页数:7
相关论文
共 44 条
  • [1] Cross-protection against European swine influenza viruses in the context of infection immunity against the 2009 pandemic H1N1 virus: studies in the pig model of influenza
    Qiu, Yu
    De Hert, Karl
    Van Reeth, Kristien
    VETERINARY RESEARCH, 2015, 46
  • [2] Protection of human influenza vaccines against a reassortant swine influenza virus of pandemic H1N1 origin using a pig model
    Arunorat, Jirapat
    Charoenvisal, Nataya
    Woonwong, Yonlayong
    Kedkovid, Roongtham
    Jittimanee, Supattra
    Sitthicharoenchai, Panchan
    Kesdangsakonwut, Sawang
    Poolperm, Pariwat
    Thanawongnuwech, Roongroje
    RESEARCH IN VETERINARY SCIENCE, 2017, 114 : 6 - 11
  • [3] The Potential of Neuraminidase as an Antigen for Nasal Vaccines To Increase Cross-Protection against Influenza Viruses
    Kawai, Atsushi
    Yamamoto, Yasuyuki
    Nogimori, Takuto
    Takeshita, Kohei
    Yamamoto, Takuya
    Yoshioka, Yasuo
    JOURNAL OF VIROLOGY, 2021, 95 (20)
  • [4] Cross-protection against a lethal influenza virus infection by DNA vaccine to neuraminidase
    Chen, Z
    Kadowaki, S
    Hagiwara, Y
    Yoshikawa, T
    Matsuo, K
    Kurata, T
    Tamura, S
    VACCINE, 2000, 18 (28) : 3214 - 3222
  • [5] A comparison of the safety, cross-protection, and serologic response associated with two commercial oral Salmonella vaccines in swine
    Husa, Jeffrey A.
    Edler, Roy A.
    Walter, Donald H.
    Holck, J. Tyler
    Saltzman, Ryan J.
    JOURNAL OF SWINE HEALTH AND PRODUCTION, 2009, 17 (01): : 10 - 21
  • [6] Peritoneal Cells Mediate Immune Responses and Cross-Protection Against Influenza A Virus
    Gautam, Avishekh
    Parke, Byoung Kwon
    Kim, Te Ha
    Akauliya, Madhav
    Kim, Dongbum
    Maharjan, Sony
    Park, Joongwon
    Kim, Jinsoo
    Lee, Hanseul
    Park, Man-Seong
    Lee, Younghee
    Kwon, Hyung-Joo
    FRONTIERS IN IMMUNOLOGY, 2019, 10
  • [7] MiRNA Targeted NP Genome of Live Attenuated Influenza Vaccines Provide Cross-Protection against a Lethal Influenza Virus Infection
    Gao, Feixia
    Yang, Tianhan
    Liu, Xueying
    Xiong, Feifei
    Luo, Jian
    Yi, Yinglei
    Fan, Jiangfeng
    Chen, Ze
    Tan, Wen-Song
    VACCINES, 2020, 8 (01)
  • [8] Cross-protection against drifted influenza viruses Options offered by adjuvanted and intradermal vaccines
    Orsi, Andrea
    Ansaldi, Filippo
    de Florentiis, Daniela
    Ceravolo, Antonella
    Parodi, Valentina
    Canepa, Paola
    Coppelli, Martina
    Icardi, Giancarlo
    Durando, Paolo
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2013, 9 (03) : 582 - 590
  • [9] Improving cross-protection against influenza virus in mice using a nanoparticle vaccine of mini-HA
    Zhu, Hechao
    Li, Xiangmin
    Ren, Xujiao
    Chen, Huanchun
    Qian, Ping
    VACCINE, 2022, 40 (44) : 6352 - 6361
  • [10] Cross-protection among Rickettsia species and subspecies in a guinea pig model of cutaneous infection
    Bechah, Yassina
    Mege, Jean-Louis
    Raoult, Didier
    COMPARATIVE IMMUNOLOGY MICROBIOLOGY AND INFECTIOUS DISEASES, 2012, 35 (06) : 551 - 556